Acumen Pharmaceuticals, Inc. ((ABOS)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Acumen Pharmaceuticals, Inc. is conducting a Phase 2 clinical trial titled ‘A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheimer’s Disease’. The study aims to assess the efficacy of sabirnetug, administered intravenously every four weeks, in slowing cognitive and functional decline in participants with early Alzheimer’s disease.
The intervention being tested is sabirnetug, an intravenous drug intended to slow the progression of Alzheimer’s symptoms. Participants receive either 35 mg/kg or 50 mg/kg doses of sabirnetug, or a placebo, during the double-blind treatment period.
This interventional study is randomized with a parallel assignment model and employs quadruple masking to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide insights into the potential benefits of sabirnetug for Alzheimer’s patients.
The study began on February 29, 2024, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on July 30, 2025, indicating the study’s ongoing status.
The outcome of this study could significantly impact Acumen Pharmaceuticals’ stock performance, as positive results may enhance investor confidence and position the company as a leader in Alzheimer’s treatment. Competitors in the Alzheimer’s drug market will be closely monitoring these developments.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.